Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23850295 | 1.00 | KMT2A (0.53) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL895125 | 1.00 | KMT2A (0.53) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL895648 | 0.94 | KMT2A (0.50) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL895798 | 0.92 | HPGD (0.54) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL2675605 | 0.88 | KMT2A (0.54) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL2675610 | 0.88 | KMT2A (0.54) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL586865 | 0.85 | KMT2A (0.56) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL586866 | 0.85 | KMT2A (0.56) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL25309754 | 0.81 | KMT2A (0.55) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL3751574 | 0.80 | KMT2A (0.58) | KMT2AMEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552786-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12528803-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3843728-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-3844162-B1 | INHIBITORS OF ALPHA V BETA6 INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | ITGB6, ITGA6, GP6 | KMT2A 3967/4885MEN1 3743/4885ALDH1A1 3568/4885 |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | KMT2A 3926/4885MEN1 3154/4885ALDH1A1 1534/4885 |
| US-12552786-B2 | Inhibitors of αvβ6 integrin | ITGB6, ITGB1, ITGA6 | KMT2A 2291/4885MEN1 3029/4885ALDH1A1 896/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | KMT2A 1554/4885MEN1 2806/4885ALDH1A1 1326/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | KMT2A 1554/4885MEN1 2806/4885ALDH1A1 1326/4885 |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | KMT2A 3926/4885MEN1 3154/4885ALDH1A1 1534/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | KMT2A 1554/4885MEN1 2806/4885ALDH1A1 1326/4885 |
| US-12528803-B2 | Inhibitors of αvβ6 integrin | ITGB2, ITGB6, ITGA2 | KMT2A 2472/4885MEN1 2751/4885ALDH1A1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.